Personalized medicine and antiplatelet therapy: ready for prime time?

Eur Heart J. 2009 Aug;30(16):1943-63. doi: 10.1093/eurheartj/ehp295. Epub 2009 Jul 28.

Authors

Céline Verstuyft¹, Tabassome Simon, Richard B Kim

Affiliation

¹ Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, 339 Windermere Road, London, Ontario N6A 5A5, Canada.

PMID: 19638479
DOI: 10.1093/eurheartj/ehp295

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aryl Hydrocarbon Hydroxylases / genetics
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / genetics
Clinical Trials as Topic
Cytochrome P-450 CYP2C19
Drug Interactions
Drug Resistance
Humans
Platelet Aggregation Inhibitors / metabolism
Platelet Aggregation Inhibitors / pharmacokinetics
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / genetics
Polymorphism, Genetic
Precision Medicine*
Proton Pump Inhibitors / therapeutic use
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Proton Pump Inhibitors
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19